Reports & White Papers

View the latest reports and white papers from the Biosimilars Council.

2022 U.S. Generic and Biosimilar Savings Report: Biosimilars Deliver on Their Promise

The 2022 U.S. Generic and Biosimilar Savings Report, the annual report from the Association for Accessible Medicines and its Biosimilars... Read more »

2021 U.S. Generic and Biosimilar Medicines Savings Report: The Promise of Biosimilars

The 2021 U.S. Generic and Biosimilar Medicines Savings Report, featuring data from IQVIA, proves that the promise of biosimilars is... Read more »

AAM Report: Securing Sustainable Markets

The first in a series of papers, this paper examines the challenges to market sustainability for generic and biosimilar medicines... Read more »
twitter chat

Global Roadmap for Tailored Clinical Biosimilar Development: Instrumental for Sustainable Access to Biologics

Following its first peer-reviewed scientific paper on biosimilar medicines development: the Path Towards Tailored Clinical Biosimilar Development (BioDrugs), the International... Read more »
biosimilars in the pharmacy

Biosimilars In The Pharmacy

Biosimilars in the pharmacy benefit employers driving appropriate use and transparency. Despite the fact that less than 2 percent of... Read more »
europe's biosimilars market

Lessons for the United States on Europe’s Biosimilar Experience

Alex Brill, Founder of Matrix Global Advisors (MGA), an economic consulting firm, and a Resident Fellow at AEI, details misconceptions... Read more »
barriers to biosimilar adoption

Biosimilars Uptake Failure

America’s health care system is eager for biosimilars, especially in light of mounting evidence that they deliver increased patient access... Read more »

Patent Abuse Blocks Access to Biosimilars for Patients

As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment. Biosimilars... Read more »

Insulin Biosimilars: Ensuring Access for America’s Diabetes Patients

Insulin has been available to America’s diabetes patients for decades. Millions rely on this medicine every day to control their... Read more »
The Biosimilars Council - 2018 Access and Savings Report Cover Zoomed In

2018 Generic Drug Access & Savings in the U.S.

This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »
The Biosimilars Council - Breaking Through on Biosimilars Whitepaper

White Paper: Breaking Through on Biosimilars

America’s patients who suffer from many complex and chronic diseases have promising new treatment options in biologic and specialty medicines.... Read more »
Patient Access Report: Biosimilars in the United States

Patient Access Report: Biosimilars in the U.S.

Biologics are medicines extracted from a variety of natural sources—human, animal or microorganism—and include a wide range of products such... Read more »

2017 Generic Drug Access and Savings in the U.S. Report

This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »

Recent Tweets

Unable to load Tweets